Biox Instruments, a wholly owned subsidiary of Vasomedical, has received approval from the Chinese Food and Drug Administration (CFDA) to begin marketing its new MobiCare Wireless Patient Monitors in China.

MobiCare Wireless Patient Monitor is a multi-parameter vital sign monitoring system, which acquires and displays multiple physiological signals, including electrocardiogram (ECG), blood pressure, respiration, peripheral capillary oxygen saturation (SpO2), body temperature.

The system also provides real-time detection and alerts for certain abnormalities in these vital signs.

Unlike traditional bedside patient monitoring systems, the MobiCare system transmits patient signals wirelessly to a touch-screen tablet receiver or a bedside monitor.

The MobiCare system’s wireless connectivity untethers patients from the bedside monitor allowing them movement within a certain range.

Initially, the Biox MobiCare system will be sold to hospitals in China as a new type of bedside patient monitor, in order to cultivate acceptance of the technology and set the stage for future introduction into the fast growing global home care market.

Vasomedical president and CEO Dr. Jun Ma said the company’s MobiCare system is a breakthrough into the relatively mature but still growing market of vital sign monitoring devices.

"More importantly, with its current configuration and planned future derivatives, the MobiCare system provides a natural bridge to telemedicine and home care systems, putting us in a strong position in these healthcare markets of the future," Dr Ma added.

"This innovative device is another example of making good on our promise to deliver advanced quality products at affordable prices so that patients all over the world may benefit as we continue to build shareholder value in our company."